COVID- 19 Drug interactions

COVID- 19 Drug interactions provides evidence-based assessments of drug–drug interactions for experimental COVID-19 therapies to inform clinical management by evaluating pharmacokinetic interactions, overlapping toxicities, and QT-prolongation risk.

Key Features:

• Comprehensive Database: Contains a curated set of 2,378 ClinicalTrials.gov records identified using search terms 'COVID-19', '2019-nCoV', '2019 novel coronavirus', and 'SARS-CoV-2', yielding 249 drugs that met inclusion criteria.
• Interaction Grading System: Categorizes interactions into four grades—GREEN (no clinically significant interaction), YELLOW (caution advised), AMBER (requires caution due to potential risks), and RED (serious risk)—to indicate severity.
• Focus on Pharmacokinetics and Toxicity: Evaluates interactions based on known pharmacokinetic profiles, overlapping toxicities, and QT interval prolongation risk.
• Highlighting High-Risk Therapies: Identifies lopinavir/ritonavir, chloroquine, and hydroxychloroquine as therapies with notable pharmacokinetic interactions and QT-prolongation risks.

Scientific Applications:

• Clinical management: Supports clinicians managing critically ill COVID-19 patients receiving experimental therapies by informing medication selection and monitoring to minimize adverse interactions.

Methodology:

Systematic search of experimental drugs on ClinicalTrials.gov using 'COVID-19', '2019-nCoV', '2019 novel coronavirus', and 'SARS-CoV-2'; evaluation of potential drug–drug interactions using pharmacokinetic data, toxicity profiles, and QT risk assessments; comorbidities identified through PubMed searches using relevant MeSH terms.